By John Vandermosten, CFA
CNSX:ORTH.CN | OTC:ORTIF
READ THE FULL ORTH.CN RESEARCH REPORT
Clinical Hold Letter Lifted
Following the April 2021 Investigational New Drug (IND) submission for Ortho-R, Ortho Regenerative Technologies Inc. (CSE:ORTH) (OTC:ORTIF) notified the public on December 13ththat the FDA had lifted its Clinical Hold on the application. Two months after its IND submission, Ortho announced that a clinical hold had been placed on the trial launch pending the collection of additional chemistry, manufacturing and control (CMC) related data and characterization of the chitosan product. On July 20th, Ortho announced that it...
Login or create a forever free account to read this news
Sign up/Log in